Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

Summary

Reinvigorating Antibiotic and Diagnostic Innovation Act of 201 7 This bill amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing expenses for: (1) infectious disease products that are intended to treat a serious or life-threatening infection, including one caused by an antibacterial or antifungal resistant pathogen or a qualifying pathogen listed by the Department of Health and Human Services as having the potential to pose a serious threat to public health; and (2) in-vitro diagnostic devices that identify in less than four hours the presence, concentration, or characteristics of a serious or life-threatening infection.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 30 March 2017

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 30 March 2017

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 30 March 2017

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.